Disease Management
619 articles
Leadership
Board of Directors Scientific Advisory Board Advisory Committee Our Team
Mike Greenstein
Mike Greenstein currently serves as the Chair of Let’s Win and is involved in several other not-for-profits where he leverages his financial services and business experience. For many years, Mike served as leader of PwC’s U.S. & Global Alternative Asset Management practice where he helped establish and significantly grow the industry’s leading practice. Mike is […]
Millicent Fortunoff
Millicent Fortunoff is President of M. Fortunoff Communications. She has extensive experience managing global and national media relations campaigns that build one reputation across regions, yet tailored to local issues and audiences. Prior to opening her own consultancy Ms. Fortunoff was a Senior Vice President in the Global Issues Communications Group at Ruder Finn (Finn […]
Betty Hudson
Betty Hudson is an award-winning communications industry leader with more than four decades of experience in every aspect of corporate and strategic communications, including consumer, employee, financial and cause related marketing, as well as brand and communications management. Having retired as Chief Communications Officer of the National Geographic Society at the end of 2015, Hudson […]
William L. McComb
William L. McComb served as Chief Executive Officer of Liz Claiborne, Inc. (renamed Fifth & Pacific Companies, Inc. in 2012) and was a member of the Company’s Board of Directors from November 6, 2006 to February 25, 2014. He led the Company’s succession in management and name to Kate Spade & Company, after successfully completing […]
Lisa Frame
Any time you read a Facebook post, share a Tweet, or view Instagram from Let’s Win, you are interacting with Lisa Frame. Lisa specializes in digital communications management and strategy. An early adopter of new technology, she was one of the first to use Twitter as a fundraising tool when she served as a colleague […]
Testing a New Drug on Advanced Pancreatic Neuroendocrine Tumors
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).